Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Valentina Zanuso"'
Publikováno v:
Journal of Liver Cancer, Vol 24, Iss 2, Pp 155-170 (2024)
Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone of advanced CCA treatment. More r
Externí odkaz:
https://doaj.org/article/1d4c8d9a1d9941468ffd1dfd83b8468d
Autor:
Valentina Zanuso, Tamsin Nash, Raffaella Casolino, Gregory Armstrong, Ona Pallise, Jen Milne, Chiara Braconi
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background With the increasing of novel therapeutics for the treatment of Biliary Tract Cancers (BTC), and the need to assess their socio-economic impacts for national licence approvals, it is as important as ever to have real-life data in n
Externí odkaz:
https://doaj.org/article/aea977adc0ee461189dd90aa214ea7c3
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 3871-3885 (2023)
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor 5-year overall survival rate (~10%). The revolution of immunotherapy in clinical oncology has not substantially changed clinical outcome for patients with PDAC. Despite outstandi
Externí odkaz:
https://doaj.org/article/8672acdd8cef4e7299fb85b75fc9c68a
Autor:
Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, Lorenza Rimassa, Ester Oneda, Caterina Soldà, Pasqua Cito, Guglielmo Nasti, Daniele Lavacchi, Valentina Zanuso, Mario Domenico Rizzato, Alberto Zaniboni, Alessandro Ottaiano, Mara Persano, Noemi Cornara, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The results of the phase III ClarIDHy trial led to the FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations. We
Externí odkaz:
https://doaj.org/article/69f677a554184995a75623a191483dc2
Autor:
Antonella Cammarota, Valentina Zanuso, Giulia Francesca Manfredi, Ravindhi Murphy, David James Pinato, Lorenza Rimassa
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
The treatment landscape of advanced hepatocellular carcinoma (HCC) has broadened with immune checkpoint inhibitors (ICIs) setting a novel standard of care. With the increased number of therapies either in first or in further line, disentangling the p
Externí odkaz:
https://doaj.org/article/b6a42a98dd9a40569a6c8535eb4b9835
Autor:
Maria Giuseppina Prete, Antonella Cammarota, Antonio D’Alessio, Valentina Zanuso, Lorenza Rimassa
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 2, Iss 5 (2021)
Biliary tract cancers (BTCs) are aggressive tumors arising from different portions of the biliary tree and classified according to the anatomical location in intrahepatic (i) cholangiocarcinoma (CCA, iCCA), perihilar CCA (pCCA), and distal CCA (dCCA)
Externí odkaz:
https://doaj.org/article/bf92c825cd1045649e37871604ff68d2
Publikováno v:
Future Science OA, Vol 6, Iss 9 (2020)
Aim: Breast cancer patients over the age of 65 are more likely to suffer chemotherapy side effects, with premature discontinuation, which negatively affects survival. Methods: We conducted a retrospective cohort study enrolling breast cancer patients
Externí odkaz:
https://doaj.org/article/ab1cd05c44184116a8494454cfbed2f1
Autor:
Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn, Hannah Hildebrand, Linda Wu, Celina Ang, Thomas U. Marron, Arndt Weinmann, Peter R. Galle, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Pei-Chang Lee, Yi-Hsiang Huang, Suneetha Amara, Mahvish Muzaffar, Abdul Rafeh Naqash, Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani, Matthias Pinter, Alessio Cortellini, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Rohini Sharma
Publikováno v:
Hepatology International.
Background Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study inv
Autor:
Eleonora Di Carlo, Antonio D'Alessio, Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani, Silvia Bozzarelli, Giuseppe Ferrillo, Giulia Vatteroni, Vittorio Pedicini, Laura Giordano, Nicola Personeni, Lorenza Rimassa
Publikováno v:
Liver Cancer International. 3:63-71
Autor:
Antonella Cammarota, Valentina Zanuso, Antonio D’Alessio, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa
Publikováno v:
Expert Opinion on Investigational Drugs. 31:401-413
Combining multikinase inhibitors (MKIs) with immune checkpoint inhibitors (ICIs) in advanced hepatocellular carcinoma (HCC) has a strong biological rationale. Among MKIs, cabozantinib seems an ideal partner for ICIs, playing a potentially synergistic